文献速递免疫规划卫生政策与健康促进

高危成人替代流感疫苗接种策略的成本效果与公共卫生影响

Cost-effectiveness and public health impact of alternative influenza vaccination strategies in high-risk adults.
PubMed 文献 · Vaccine · 2017-09-07

本研究用马尔可夫模型比较50-64岁人群5种流感疫苗接种策略的成本效果。结果显示仅接种标准剂量三价灭活疫苗总成本最低(每人99.84美元),仅接种四价疫苗每增加0.91美元/人、每获得一个质量调整生命年需37,700美元,高危人群用高剂量三价、其他人用四价策略较仅四价策略多花1.06美元/人、每获得一个质量调整生命年需71,500美元;不接种和高危用高剂量三价、其他人用标准三价两策略被支配。作者认为基于现有数据,在中高龄高危人群中用高剂量疫苗或重组疫苗可能是有经济性且具公共卫生效益的策略,该人群的临床试验可能有必要。

要点

  • 50-64岁人群仅接种标准剂量三价灭活疫苗总成本最低,为每人99.84美元。
  • 仅接种四价疫苗较仅接种三价疫苗每人多花0.91美元,每获得一个质量调整生命年需37,700美元。
  • 高危用高剂量三价、其他人用四价策略较仅四价策略每人多花1.06美元,每获得一个质量调整生命年需71,500美元。

核心结论

  • 基于现有数据,在50-64岁高危患者中使用高剂量流感疫苗或重组三价流感疫苗可能是有经济性且具公共卫生效益的接种策略,该人群的临床试验可能有必要。

研究设计与样本

  • 马尔可夫模型成本效果分析,在50-64岁人群中比较5种策略:不接种、仅提供标准剂量三价灭活疫苗、仅提供四价流感疫苗、高危患者接种高剂量三价灭活疫苗而其他人接种标准剂量三价灭活疫苗、高危患者接种高剂量三价灭活疫苗而其他人接种四价流感疫苗;二次分析以重组三价流感疫苗替代高剂量三价灭活疫苗。
  • 参数来自美国数据库、医学文献及疫苗有效性估计的外推,效果以每年避免3%折现的质量调整生命年损失衡量。

主要发现

  • 仅接种标准剂量三价灭活疫苗策略总成本最低,为每人99.84美元。
  • 仅接种四价流感疫苗策略较仅接种标准剂量三价灭活疫苗策略每人多花0.91美元,每获得一个质量调整生命年需37,700美元。
  • 高危接种高剂量三价灭活疫苗、其他人接种四价流感疫苗策略较仅接种四价流感疫苗策略每人多花1.06美元,每获得一个质量调整生命年需71,500美元。
  • 不接种策略和高危接种高剂量三价灭活疫苗、其他人接种标准剂量三价灭活疫苗策略被支配。
  • 结果对流感发病率、疫苗成本、全人群标准剂量疫苗有效性和高危患者高剂量疫苗有效性敏感;重组三价流感疫苗用于高危患者的成本效果取决于尚不清楚的参数值。

局限性

  • 重组三价流感疫苗用于高危患者的成本效果取决于尚不清楚的参数值。
  • 作者结论提出该人群的临床试验可能有必要。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: High-dose trivalent inactivated influenza vaccine (HD-IIV3) or recombinant trivalent influenza vaccine (RIV) may increase influenza vaccine effectiveness (VE) in adults with conditions that place them at high risk for influenza complications. This analysis models the public health impact and cost-effectiveness (CE) of these vaccines for 50-64year-olds. METHODS: Markov model CE analysis compared 5 strategies in 50-64year-olds: no vaccination; only standard-dose IIV3 offered (SD-IIV3 only), only quadrivalent influenza vaccine offered (SD-IIV4 only); high-risk patients receiving HD-IIV3, others receiving SD-IIV3 (HD-IIV3 & SD-IIV3); and high-risk patients receiving HD-IIV3, others receiving SD-IIV4 (HD-IIV3 & SD-IIV4). In a secondary analysis, RIV replaced HD-IIV3. Parameters were obtained from U.S. databases, the medical literature and extrapolations from VE estimates. Effectiveness was measured as 3%/year discounted quality adjusted life year (QALY) losses avoided. RESULTS: The least expensive strategy was SD-IIV3 only, with total costs of $99.84/person. The SD-IIV4 only strategy cost an additional $0.91/person, or $37,700/QALY gained. The HD-IIV3 & SD-IIV4 strategy cost $1.06 more than SD-IIV4 only, or $71,500/QALY gained. No vaccination and HD-IIV3 & SD-IIV3 strategies were dominated. Results were sensitive to influenza incidence, vaccine cost, standard-dose VE in the entire population and high-dose VE in high-risk patients. The CE of RIV for high-risk patients was dependent on as yet unknown parameter values. CONCLUSIONS: Based on available data, using high-dose influenza vaccine or RIV in middle-aged, high-risk patients may be an economically favorable vaccination strategy with public health benefits. Clinical trials of these vaccines in this population may be warranted.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Raviotta JM, Smith KJ, DePasse J, et al. Cost-effectiveness and public health impact of alternative influenza vaccination strategies in high-risk adults. Vaccine. 2017. PMID: 28890196. doi:10.1016/j.vaccine.2017.07.069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。